Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTO7LKR)

• DTT Name: Tyrosine-protein kinase Mer (MERTK) DTT Info
• UniProt ID: MERTK_HUMAN
• Gene Name: MERTK

Molecule-Related Drug & Molecule List

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[1]
ONO-7475	DMV6GX7	Acute leukaemia	2A60	Phase 1/2	[2]
INCB81776	DMFOXGB	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
MRX-2843	DMM5N8P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
ONO-7475	DMGBKCJ	Acute myeloid leukaemia	2A60	Phase 1	[5]
PF-07265807	DMSMNRQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
RXDX-106	DM6NVTR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]

4 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
G749	DMC7HIS	Discovery agent	N.A.	Investigative	[8]
LDC1267	DMH7R6L	Discovery agent	N.A.	Investigative	[9]
UNC2025	DMCU59W	Glioblastoma of brain	2A00.00	Investigative	[10]
UNC569	DMJL6ZM	Acute lymphoblastic leukaemia	2A85	Investigative	[11]

References

• [1] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [2] Clinical pipeline report, company report or official report of Ono Pharmaceutical.
• [3] A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477.
• [4] The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] National Cancer Institute Drug Dictionary (drug name PF-07265807).
• [7] National Cancer Institute Drug Dictionary (drug name RXDX106).
• [8] G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123(14):2209-19.
• [9] The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12.
• [10] MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018 Jan 10;20(1):92-102.
• [11] UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013 Nov;12(11):2367-77.